CD8A and cholangiocarcinoma: In the realm of cholangiocarcinoma, Akihiko Kida et al.’s investigation into immune responses against TAA-derived CD8+ T-cell epitopes identified KIF20A among other TAAs as promising targets for immunotherapy.